Washington, D.C.—The Council for Responsible Nutrition (CRN) announced the launch of an education campaign to inform consumers of upcoming dietary supplement label changes in a press release. The “Label Wise” campaign, the release says, calls specific attention to the “Supplement Facts” label changes mandated by FDA. It offers easy-to-understand information...
Washington, DC–Before vacating his office on April 5, former FDA Commissioner Scott Gottlieb, M.D., shared his thoughts on the most efficient pathway to legalize CBD. As WholeFoods previously reported, Dr. Gottlieb attended his final hearing before a Senate appropriations subcommittee in March. When questioned about CBD, he stated that the...
Silver Spring, MD—FDA has set a time and date for a public hearing regarding products containing cannabis-derived compounds, according to a public announcement. The hearing—titled “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds”—will take place on May 31, 2019, from 8:00 a.m.-6:00 p.m. at FDA’s White Oak...
Washington, D.C.--The U.S. Food and Drug Administration (FDA) sent four warning letters about violations of current good manufacturing practice (CGMP) regulations to companies that produce homeopathic drug products, including King Bio Inc., Red Mountain Inc., Tec Laboratories Inc. and B. Jain Pharmaceuticals Pvt. Ltd., according to a news release. The...
Washington, D.C.—Outgoing FDA commissioner Scott Gottlieb was asked about the FDA’s plan to regulate hemp-derived CBD products at his final hearing before a Senate appropriations subcommittee. According to a report by Marijuana Moment, Senator Patrick Leahy (D-VT) pointed out the “significant regulatory and enforcement uncertainty” surrounding CBD, and asked Dr. Gottlieb how...
Washington, DC--Outgoing FDA Commissioner Scott Gottlieb shared his thoughts on the the most efficient pathway to legalize CBD while speaking at a talk hosted by the Hutchins Center on Fiscal & Monetary Policy and the USC-Brookings Schaeffer Initiative for Health Policy at Brookings Institution. After his talk, Gottlieb was interviewed by...
Washington, D.C.—Commissioner Scott Gottlieb’s departure doesn’t seem to be slowing the FDA down any, if the spate of industry-affecting actions taken on the 19th means anything. The FDA posted a warning letter to Nutra Pharma Corp. for illegally marketing unapproved products with claims about their ability to treat addiction and...
New York—KIND Healthy Snacks filed a Citizen Petition urging the FDA to update the nutrient content claim regulation, according to a press release, which says that the current regulation looks at quantities of specific nutrients irrespective of the quality of the overall food, enabling food marketers to put health claims...
Washington, D.C.—Dr. Norman E. Sharpless, director of the National Cancer Institute, will serve as acting commissioner of the Food and Drug Administration, according to the New York Times, which cited an announcement by Alex M. Azar III, the secretary of Health and Human Services. Dr. Sharpless has been director of...
Washington, D.C.—Scott Gottlieb, commissioner of the Food and Drug Administration, announced his resignation, effective in April. The announcement came at the start of Expo West, causing much buzz and speculation as to what had led to the resignation—and what the impact would be for the natural products industry. The New...
